Bebtelovimab is an antiretroviral drug that is administered intravenously. Bebtelovimab is indicated for the treatment of mild to moderate disease caused by coronavirus. However, the drug Bebtelovimab can cause unwanted side effects: shortness of breath, high blood pressure, chills... Therefore, patients need to learn quite carefully about the information of the drug and comply with the indications. doctor.

At present, it is not entirely clear what causes liver failure during the covid-19 infection. However, covid-19 infection is characterized by significant activation of cytokine cascade, sepsis, and altered hepatic perfusion that can identify significant depletion of liver reserve in cirrhosis.

It has been documented that covid-19 patients with gastrointestinal symptoms show a higher rate of liver damage than patients without gastrointestinal symptoms.

According to the US CDC, pregnant women with Covid-19 are at higher risk of severe illness than non-pregnant women. However, the mortality rate does not differ between pregnant and non-pregnant women.

Covid-19 is a disease with symptoms similar to colds, flu, and allergies, so it is easy to confuse. Therefore, the best way to confirm the disease early is to perform screening tests when in contact with people returning from epidemic areas with symptoms of the disease.

Acute pharyngitis is one of the most common diseases in the community. Most cases of acute pharyngitis are caused by respiratory viruses and are self-limiting. However, the symptoms of viral pharyngitis often overlap with those of pharyngitis caused by serious, treatable causes.

On January 5, 2020, WHO issued a global alert after 44 patients were hospitalized with pneumonia of unknown cause, reported by the national authorities of China. On March 11, 2020, WHO declared the novel coronavirus, identified as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and causing the so-called coronavirus disease 2019 (COVID-19), a pandemic.

Compelling evidence supports the important role of the receptor in the activation of the advanced glycation end products axis (ADG) in multiple clinical entities. Since the onset of the 2019 coronavirus pandemic, concerns have been growing about the risk and management of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in inflammatory gastrointestinal disorders, such as inflammatory bowel disease (IBD).

Compelling evidence supports the important role of the receptor in activating the advanced glycation end product axis (ADG) in multiple clinical entities. Since the onset of the 2019 coronavirus pandemic, concerns have been growing about the risk and management of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in inflammatory gastrointestinal disorders, such as inflammatory bowel disease (IBD). However, clinical data collected during the pandemic suggest that patients with IBD are not at increased risk of SARS-CoV-2 infection or developing a more severe course of infection.

Many studies have shown that liver injury is common in patients with coronavirus disease 2019 (COVID-19) and may exacerbate disease severity. However, the exact cause and specific mechanism of COVID-associated liver injury need to be further elucidated.

At present, the reasons for liver failure in covid-19 infection are not fully understood. However, covid-19 infection is characterized by significant activation of the cytokine cascade, sepsis, and changes in liver perfusion, which may determine a significant decrease in liver reserve in cirrhosis.